Pacira BioSciences Inc. (NASDAQ: PCRX) is asking stockholders to vote for its three director nominees ahead of its June 9, 2026 annual meeting, opposing candidates put forward by DOMA Perpetual Capital Management LLC.

The company is urging stockholders to vote for Christopher Christie, Samit Hirawat and Thomas Wiggans on the blue proxy card. Three proxy advisory firms - ISS, Glass Lewis and Egan-Jones - have recommended voting for Pacira's nominees and against DOMA's candidates.

Pacira reported first quarter 2026 revenue increases across its product portfolio. EXPAREL revenue reached $143.3 million, up 5% year-over-year, while ZILRETTA revenue grew 15% to $26.8 million and iovera revenue increased 21% to $6.2 million.

The company achieved record financial results in 2025, including total revenue of $726.4 million and non-GAAP gross margins of 81.2%. Pacira is advancing clinical trials for PCRX-201 in knee osteoarthritis and registrational studies for ZILRETTA in shoulder osteoarthritis.

DOMA Perpetual has nominated three candidates to Pacira's board as part of a proxy contest. Pacira argues that DOMA's nominees lack relevant biopharmaceutical expertise and public company board experience.

The company operates in the non-opioid pain therapy market with three commercial products: EXPAREL for postsurgical pain management, ZILRETTA for osteoarthritis knee pain, and iovera for drug-free pain control.